Primary sclerosing cholangitis (PSC) is a liver disorder that causes bile duct inflammation and scarring (fibrosis). These ducts are tubes that allow the liver’s fluids (bile) to travel through the colon, allowing fat breakdown to take place. Men between the ages of 25 and 40 are disproportionately affected by this condition. Damage to the ducts results in a buildup of bile acids, which are key components of bile, in the liver, causing liver tissue damage, portal hypertension (high blood pressure in the veins connecting the liver and the gut), and liver failure, as well as an increased risk of liver cancer.
Get Sample Report with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-sample/1960
A comprehensive study on the impact of the Covid-19 pandemic on the global Primary Sclerosing Cholangitis Market is also crafted in the report. Over five products are currently undergoing Phase 2 clinical studies, with some of them showing promising results. Intercept Pharmaceuticals, Inc., for example, is conducting the ASEOP study, which is investigating Obeticholic acid (OCA) for primary sclerosing cholangitis. In February 2016, Shire Plc. completed a Phase 2 clinical trial for the therapeutic candidate LUM001.
These prospective compounds would be among the first to receive regulatory approval for this condition if they make it through the advanced clinical trials phase (i.e. Phase 3) and win regulatory approval.
Furthermore, the majority of patients live in developed economies such as Europe and North America, where diagnosis rates and affordability are generally higher than in emerging economies such as Asia Pacific, resulting in a higher rate of adoption of novel products with significantly higher yearly costs (i.e. more than US$ 50,000 for orphan drugs). Due to the above mentioned factors, the global primary sclerosing cholangitis market is expected to reach US$ 140.4 Mn by 2023.
However, the withdrawal of prospective therapeutic compounds from late-stage clinical trials has limited the availability of effective treatment, forcing patients to turn to bile acid sequestrants, antibiotics, antihistamines, opioid antagonists, and ursodeoxycholic acid as alternatives (UDCA).
Current medicinal interventions, such as ursodeoxycholic acid, improve liver enzymes, according to a study published in the Gastroenterology and Hepatology Journal in 2016. It does not, however, stop PSC from progressing or lower the chance of recurrence. Thus, unavailability of approved drugs targeting the condition in practical medical use is a factor hindering growth of the global primary sclerosing cholangitis market.
Want to “ahead” with your competiors request a PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/1960
The rising frequency of disorders linked to PSC, such as liver cancer and inflammatory bowel disease, is likely to boost therapeutic acceptance of effective pharmaceuticals to treat the condition, propelling the primary sclerosing cholangitis market forward.. Inflammatory bowel disease (IBD) is detected in 50-80 percent of patients with PSC, according to the World Journal of Gastroenterology, with ulcerative colitis (UC) accounting for 80-90 percent of these instances.
Furthermore, those with PSC are more likely than the general population to develop cholangiocarcinoma, a cancer of the bile ducts. According to the National Organization for Rare Disorders (NORD), approximately 8-15 percent of PSC patients develop cholangiocarcinoma and are at an increased risk of gall bladder cancer. Patients with PSC are also more likely to develop Crohn’s disease, colon cancer, and immune-mediated illnesses such thyroid disease, Peyronie’s disease, retroperitoneal fibrosis, psoriasis, rheumatoid arthritis, Celiac disease, and others, according to NORD.
Currently, liver transplant is the only known cure for primary sclerosing cholangitis and is one of the major causes for liver transplantation in the U.S. However, as per the survey by Mayo Clinic, the disease is expected to recur in the transplanted liver in 27.2% of the patients, thereby demanding efficient and affordable therapeutic solutions to cater to unmet patient needs. According to the United Network for Organ Sharing (UNOS), 2011, estimated bill charges of a liver transplant procedure is around US$ 577,100 in the U.S.
As a result of the high costs associated with liver transplantation, as well as increased risk factors leading in the development of significant illnesses, the adoption of PSC medicines is likely to rise, boosting market expansion in the near future.
Major players operating in the global primary sclerosing cholangitis market include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
Reasons to Purchase this Report
• Current and future of global Primary Sclerosing Cholangitis market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
Global Primary Sclerosing Cholangitis Market Research Report
Section 1: Global Primary Sclerosing Cholangitis Industry Overview
Section 2: Global Economic Impact on Primary Sclerosing Cholangitis Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Primary Sclerosing Cholangitis Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837